Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC – OncLive
OncLiveImmunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCCOncLiveAn extension in overall survival (OS) seen with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) has completely changed the standard of care for … Continue reading
